Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Common Equity (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Common Equity data on record, last reported at $231.1 million in Q3 2025.

  • For Q3 2025, Common Equity rose 211.47% year-over-year to $231.1 million; the TTM value through Sep 2025 reached $231.1 million, up 211.47%, while the annual FY2024 figure was $139.6 million, 32.25% up from the prior year.
  • Common Equity reached $231.1 million in Q3 2025 per TNXP's latest filing, up from $168.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $231.1 million in Q3 2025 and bottomed at $42.1 million in Q2 2024.
  • Average Common Equity over 3 years is $134.2 million, with a median of $139.6 million recorded in 2024.
  • Peak YoY movement for Common Equity: crashed 70.03% in 2024, then surged 299.02% in 2025.
  • A 3-year view of Common Equity shows it stood at $105.5 million in 2023, then soared by 32.25% to $139.6 million in 2024, then surged by 65.63% to $231.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $231.1 million in Q3 2025, $168.0 million in Q2 2025, and $180.4 million in Q1 2025.